KVD824

KVD824 is a potent and selective small-molecule inhibitor of plasma kallikrein, developed for the prophylactic treatment of hereditary angioedema (HAE) types I and II. Plasma kallikrein is a key enzyme in the pathogenesis of HAE attacks, as its activity leads to increased production of bradykinin, which causes vascular permeability and tissue swelling. By inhibiting plasma kallikrein, KVD824 was designed to prevent or reduce the frequency and severity of HAE attacks. The drug was administered orally in modified-release tablets at doses ranging from 300 mg to 900 mg twice daily. Clinical development included Phase 1 studies in healthy volunteers and a Phase 2 trial (KOMPLETE) in HAE patients; however, development was terminated due to safety concerns related to elevated liver enzymes observed during the trial[2][3][5][6][7].